All News
Filter News
Found 4,569 articles
-
CANbridge Consolidates Gene Therapy Portfolio
1/4/2023
CANbridge Pharmaceuticals, Inc. announced that it has exercised its option to secure the exclusive global rights to develop, manufacture and commercialize a novel second-generation gene therapy to treat spinal muscular atrophy from UMass Chan Medical School.
-
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate
12/29/2022
Pfizer Inc. announced positive top-line results from the Phase 3 BENEGENE-2 study evaluating fidanacogene elaparvovec, an investigational gene therapy, for the treatment of adult males with moderately severe to severe hemophilia B.
-
Mergers and acquisitions are expected to be a key theme in the pharmaceutical industry in 2023.
-
Cell and Gene Therapy Market Size To Expand USD 93.78 Bn By 2030
12/23/2022
The global cell and gene therapy market size was exhibited at USD 18.61 billion in 2022 and is expected to expand around USD 93.78 billion by 2030, poised to grow at a projected CAGR of 22.41% from 2022 to 2030.
-
Plasma Derived Therapy Market Size To Hold USD 33.75 Bn By 2030
12/21/2022
The global plasma derived therapy market size was exhibited at USD 19.54 billion in 2022 and it is expected to hold around USD 33.75 billion by 2030, growing at a CAGR of 7.07% from 2022 to 2030.
-
Orsini Specialty Pharmacy Selected by CSL Behring as a Limited Distribution Partner for HEMGENIX®, the First and Only Gene Therapy for Hemophilia B
12/20/2022
Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, was selected by CSL Behring https://www.gilead.com/ as a limited distribution partner for HEMGENIX® (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy option for hemophilia B.
-
Recombinant Adeno-Associated Virus (rAAV) Technology Pioneered by AskBio's Dr. Jude Samulski is Key Component of All FDA Approved AAV Gene Therapeutics
12/20/2022
Asklepios BioPharmaceutical, Inc. (AskBio) today announced that the FDA's approval of a new adeno-associated virus (AAV) gene therapy to treat adults with hemophilia B marks another milestone for the advancement of AAV therapeutics and highlights the important research contributions made by AskBio Co-Founder, President and Chief Scientific Officer, R. Jude Samulski, PhD.
-
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/20/2022
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to employees as a material inducement to commencing their employment.
-
uniQure announces positive CHMP opinion for etranacogene dezaparvovec
12/16/2022
uniQure N.V. announced that its partner, global biotechnology leader CSL (ASX: CSL), has received a positive opinion recommending conditional marketing authorization (CMA) for etranacogene dezaparvovec from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
-
Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day
12/15/2022
Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, is hosting a virtual R&D Day today.
-
Spark Therapeutics Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A
12/12/2022
Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated gene therapy company today announced updated multi-year results from its Phase 1/2 clinical trial of investigational SPK-8011 for patients with hemophilia A.
-
Interim Data From Phase III Study Presented at ASH 2022 Show Hemlibra (emicizumab-kxwh) Achieved Meaningful Bleed Control in Infants From Birth
12/11/2022
Genentech, a member of the Roche Group, announced interim results from the Phase III HAVEN 7 study.
-
Coagulant Therapeutics Presents Data on an Exosite-Specific Nanobody Library to Activated Protein C (APC) at the 2022 American Society of Hematology (ASH) Annual Meeting
12/11/2022
Coagulant Therapeutics Corporation announced data from pre-clinical studies on a novel llama-derived antibody library directed to the APC exosite.
-
Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition
12/11/2022
Poseida Therapeutics, Inc. announced that the Company will present preclinical data from its P-FVIII-101 gene therapy program, partnered with Takeda, at the 2022 American Society of Hematology Annual Meeting being held in New Orleans and virtually December 10–13, 2022.
-
Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia
12/10/2022
Centessa Pharmaceuticals plc, announced new data from an additional 18-months of continued treatment with SerpinPC, an investigational, subcutaneously administered novel inhibitor of activated protein C, from the open-label extension of the Phase 2a study of SerpinPC for hemophilia.
-
CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment
12/10/2022
Global biotechnology leader CSL announced the presentation of data affirming the long-term durability and safety of single-infusion HEMGENIX® in the treatment of certain adults living with hemophilia B at the 64th American Society of Hematology Annual Meeting.
-
Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases
12/9/2022
Takeda (TSE:4502/NYSE:TAK) today announced that it will present 15 company-sponsored abstracts at the 64th American Society of Hematology (ASH) Annual Meeting being held December 10-13, 2022 in New Orleans.
-
Sernova Corp. Announces CEO Succession Plan and Expanded Management TeamThe Company is recruiting a new CEO for its next stage of growth - Dr. Toleikis, President and CEO, to transition to Chief Technology Officer upon new appointment
12/6/2022
Sernova Corp. announced today that, as part of a planned leadership succession process, and after a successful 13-year tenure leading the Company through the development of its pioneering Cell Pouch System™ and ensuing growth, Dr. Philip Toleikis, President and Chief Executive Officer will be appointed Sernova’s Chief Technology Officer.
-
Vega Therapeutics launches and unveils its first-in-class antibody therapy for von Willebrand disease at ASH Annual Meeting
12/6/2022
Vega Therapeutics, Inc. today announced its launch and oral presentation of its first-in-class antibody therapy, VGA039, at the 64th American Society of Hematology (ASH) Annual Meeting.
-
Home to many of the world's leading life science companies, the Genetown hotbed is a hub of activity. To help you in your job search, here are 10 Massachusetts biopharma companies hiring now.